zuretinol (BBP-551) / BridgeBio, Eluminex Bio - LARVOL DELTA

Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease (clinicaltrials.gov) - P2/3 | N=0 | Withdrawn | Sponsor: Retinagenix Holdings | N=45 ➔ 0 | Suspended ➔ Withdrawn

Enrollment change • Trial withdrawal • Ophthalmology • Retinal Disorders

Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease (clinicaltrials.gov) - P2/3; N=45; Suspended; Sponsor: Retinagenix Therapeutics; Initiation date: May 2020 ➔ Dec 2020; Not yet recruiting ➔ Suspended

Clinical • Trial initiation date • Trial suspension • Ophthalmology • Retinal Disorders

Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease (clinicaltrials.gov) - P2/3; N=45; Not yet recruiting; Sponsor: Retinagenix Therapeutics

Clinical • New P2/3 trial

PK model with concentration-dependent clearance for zuretinol acetate, an oral agent in development for treatment of inherited retinal dystrophy caused by LRAT or RPE65 mutations (ARVO 2020) - "This unique finding suggests that there may be recycling of 9-cis-retinol to afford protection of the visual cycle as an adaptive protection for preservation of vision.A model to describe the behavior of zuretinol acetate, an oral agent in development for treatment of inherited retinal dystrophy caused by LRAT or RPE65 mutations, is described. It has useful implications regarding the potential for dosing"